Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Date:2/21/2008

NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... 22, 2014 The Board of Directors of BD ... declared a quarterly dividend of 54.5 cents per common share ... September 9, 2014. The indicated annual dividend rate is $2.18 ... is a leading medical technology company that partners with customers ... and evolving health needs. Our innovative solutions are focused on ...
(Date:7/22/2014)... a solution of rod-shaped metal nanoparticles in water with ... tiny drill bits. Why? No one yet knows exactly. ... Technology (NIST) have clocked their speedand it,s fast. At ... 10 times faster than any nanoscale object submerged in ... rate has opened up the possibility that they could ...
(Date:7/22/2014)... 2014 Nuclear reactors are used to ... controlled fission chain reaction in nuclear reactors is used ... to drive a power- generating turbine. Currently nuclear reactors ... total electricity production. Nuclear reactor market is expected to ... and proposed nuclear reactor projects. , Early buyers will ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... SAN DIEGO, CA, March 30, 2009 Senomyx, Inc. ... on using proprietary technologies to discover and develop novel ... industries, announced today the extension of the collaborative research ... with Campbell Soup Company, a global manufacturer and marketer ...
... Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) will ... and interested parties in Zurich, Switzerland on April 1, ... update the investment community on the company,s business.Company chairman ... answer shareholder questions along with the ...
... March 30 BioVex Inc, a company developing new ... and infectious disease, announced today it has raised $40 ... private financing.The placement was led by Forbion Capital Partners, ... Agricole Private Equity, Harris & Harris Group, Innoven Partners, ...
Cached Biology Technology:SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 2SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 3Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland 2BioVex Raises $40 Million in First Close of Series F Financing 2BioVex Raises $40 Million in First Close of Series F Financing 3
(Date:7/23/2014)... of getting tangled and forming knots. Scientists study these ... disentangle them (e.g. useful for gene sequencing techniques). Cristian ... (SISSA) in Trieste and his team have been carrying ... their dynamics. In their latest paper, just published in ... Marco Di Stefano, first author and PhD student at ...
(Date:7/23/2014)... called Blastocystis can be beneficial to human health, ... our views of organisms that live off the human body. ... ingested three developmental stages of a large species of tapeworm ... with the tapeworms, which might have grown to be as ... feels fine. , "I knew there was no risk," he ...
(Date:7/23/2014)... packed with healthful compounds, and now lab tests show ... prescription anti-diabetic medication, scientists report. In their new study ... Chemistry , they found that how the herbs are ... compounds contribute the most to this promising trait. , ... in 2012, type-2 diabetes affected more than 8 percent ...
Breaking Biology News(10 mins):Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3
... monarch butterflies ( Danaus plexippus ) migrate from overwintering ... but just how these delicate creatures manage to reach ... has largely remained a mystery. Monarch ButterflyNew research ... Norris, Department of Integrative Biology, former graduate student Nathan ...
... first line defence of the brain and are constantly ... cause uncontrolled inflammation within the brain, which can in ... BioMed Central,s open access journal Journal of Neuroinflammation ... the production of pro-inflammatory cytokines and inflammatory enzymes in ...
... ever more ubiquitous, researchers are using it to make ... diagnose diseases, learn more about inherited traits, and more. But ... always a tradeoff between how long any measurement takes to ... is very weak, the tradeoff is especially big. ...
Cached Biology News:Study reveals how monarch butterflies recolonize northern breeding range 2The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage 2Columbia Engineering and Penn researchers increase speed of single-molecule measurements 2Columbia Engineering and Penn researchers increase speed of single-molecule measurements 3
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... Plus Western Blotting Reagent Pack, 1. ... detection of membrane-bound mouse and rabbit primary ... PVDF membranes. Detection reagents are not included, ... with ECL Plus. Category: Blotting & ...
... FHS-LVF and CVD-Diffuse We've combined our ... to create the world's first notch filter ... bandpass. Each filter features an excellent transmission ... These filters -- with interference coatings applied ...
Biology Products: